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Abstract
When confronted with a septic patient or dealing with an emerging epidemic, clinicians, infection control specialists and microbiologists
have often felt an immense ‘need for speed’ while waiting for culture results. Various mass spectrometry (MS) applications are about to
answer most of their demands. Matrix-assisted laser desorption ionization (MALDI) time-of-ﬂight (TOF) MS of whole bacterial cells has
already greatly shortened the time needed for identiﬁcation of a positive culture in major diagnostic laboratories in Europe. MS is
described in this article, with a special emphasis on the different systems currently commercially available for routine identiﬁcation.
MALDI-TOF MS remains, however, limited by the previous time-consuming culture steps, and is not suited for strain typing in epidemic
contexts. These limitations can be overcome by other applications of MS in microbiology. MALDI–resequencing is a rapid method for
genotyping, offering comparable results to multilocus sequence typing. New systems of broad-range PCR, associated with analyses of
amplicons by electrospray ionization MS, might allow nearly full automation for the direct identiﬁcation of pathogens in blood, thus
bypassing the culture stage. This article describes various applications of MS methods in clinical microbiology, and provides a compara-
tive table of these technologies.
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Introduction
The primary mission of a clinical bacteriology laboratory is
to assist clinicians in the diagnosis and treatment of infec-
tious diseases, and to support infection control specialists in
their tasks. In many instances, however, the delay between
the collection of the specimen and the results of the bacte-
rial culture makes the latter unhelpful for the clinician [1].
There is a ‘need for speed’, as rapid identiﬁcation of a patho-
gen is of prime importance for effective patient management.
It gives a clue towards the primary site of infection, and
often reduces the use of empirical broad-spectrum antibiotic
therapy to a more narrow pre-emptive treatment, based
on the usual susceptibilities (or natural resistance) of the
pathogen.
Despite relentless efforts to develop rapid, cost-effective
and reliable methods for diagnosis, the time required for the
bacterial identiﬁcation of a positive culture has, for many
years, been between 24 and 72 h. However, advances in
mass spectrometry (MS) in the analysis of proteins and,
more recently, DNA are opening up new vistas in the ﬁeld
of diagnostic microbiology. Fig. 1 gives a global view of the
role of the various applications of MS in shortening the time
to identiﬁcation or typing of a bacterium.
The major contribution to this ‘ongoing revolution in
microbiology’ [2] is being brought about by matrix-assisted
laser desorption ionization time-of-ﬂight MS (MALDI-TOF
MS), a technology that is only about 20 years old. Its ability
to analyse whole bacterial cells with virtually no sample
preparation has drastically improved the time to identiﬁca-
tion of a positive culture (1–2 min, starting with a colony),
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especially when it is performed directly on positive blood
cultures (1 h, owing to the extraction protocol) [3–6].
Nevertheless, rapid identiﬁcation of bacterial pathogens
directly from the blood of septic patients remains a chal-
lenge. With the limits of MS being continually expanded, it
seems highly likely that in the future it will provide solutions
for bacterial identiﬁcation even before in vitro culture.
The ﬁrst description of the use of MS for bacterial identiﬁ-
cation was in 1975 [7]. A period of intense mass spectral
analysis of lipids such as menaquinones in the 1980s wit-
nessed the restructuring of many genera [8]. However, it
took a long time for MS technology to enter routine micro-
biology. This was because of the limited mass range
(<1500 Da), which restricted its applications to small mole-
cules such as various bacterial lipids [8]. Proteins are orders
of magnitude greater, and their analysis by MS had to await
the arrival of soft ionization techniques such as MALDI and
electrospray ionization (ESI) [9]. A process of continual
development of the hardware began, providing increasing
accuracy and resolution of proteins, and soon the ﬁrst
benchtop MALDI-TOF MS instruments became available.
This was more suitable for a microbiology laboratory, and
by the mid-1990s MALDI-TOF MS was being used for the
identiﬁcation of bacteria in research settings [10,11]. A few
years later, the ﬁrst complete database for bacterial identiﬁca-
tion, based on the analysis of surface molecules of bacterial
cells, was reported [12]. This approach was expected to
allow not only the identiﬁcation of bacteria to the species
level, but also the identiﬁcation of key surface-associated
molecules, such as virulence factors. However, it was not well
suited for routine bacteriology, as it necessitated rigorous
standardization, owing to the variation in surface proteins.
A more robust approach for species identiﬁcation was
then developed, using MALDI-TOF MS but involving the use
of a different matrix. The change of matrix permitted the
ionization of mainly ribosomal proteins, which are more con-
served than surface proteins [13]. This was considered to be
more reliable for routine identiﬁcation of bacterial species,
as culture conditions seemed to have little effect on the
results of identiﬁcation [14]. During the last 4 years, com-
mercial systems with comprehensive and secure databases,
as well as user-friendly software, have been developed for
routine use. Two of the MS companies, Bruker Daltonics
and Shimadzu, provide hardware. The Bruker instrument
provides its own solution, MALDI BioTyper (software, bioin-
formatic and database), whereas the Shimadzu instrument
uses its own software (Launchpad) and the SARAMIS data-
base developed by AnagnosTec GmbH and recently acquired
FIG. 1. Time to identiﬁcation or typing: the role of mass spectrometry. MALDI-TOF MS, matrix-assisted laser desorption ionization time-of-
ﬂight mass spectrometry; MALDI-RE, matrix-assisted laser desorption ionization–eesequencing; PCR-ESI-MS,PCR–electrospray ionization mass
spectrometry; ID, identiﬁcation; MLST, multilocus sequence typing; AB, antibiogram.
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by BioMe´rieux. Andromas provides a different type of data-
base and software for routine bacteriology, compatible with
either Bruker or Shimadzu hardware. These MALDI-TOF MS
technologies are already replacing most of the biochemical
tests currently used for bacterial identiﬁcation in our labora-
tory, as well as in many other high-throughput laboratories
in Europe.
In research settings, however, the use of MS has been
further promoted with the development of MALDI-
resequencing (MALDI-RE) and PCR-ESI-MS. Both MALDI-RE
and PCR-ESI-MS are based on the use of MS to analyse
nucleic acids, with promising results for the genotyping of
bacteria [15–17] and the identiﬁcation of pathogens directly
from clinical samples [15,18]. However, DNA denatures in
MALDI, so there is a need for conversion to RNA, whereas
ESI permits the direct spectrometric analysis of DNA
amplicons.
A description of the MS tools currently available for clini-
cal and research microbiology laboratories is presented
herein. This article also attempts to compare them in terms
of robustness, cost, and sensitivity for identiﬁcation and/or
typing (Table 1).
MALDI-TOF MS
Principle
Sample culture is performed as previously, and remains the
main limitation to timely identiﬁcation of a pathogen in a
clinical sample. However, instead of using traditional pheno-
typic identiﬁcation schemes, MALDI-TOF MS is used for the
identiﬁcation of colonies. Fig. 2 describes the principle of
MALDI-TOF MS.
This new method of identiﬁcation of microorganisms,
based on molecular instead of phenotypic identiﬁcation, has
proven to be reliable and safe for the identiﬁcation of Entero-
bacteriacae [19], a majority of non-fermenters [20,21], staph-
ylococci [22,23], enterococci and b-haemolytic streptococci.
This has been conﬁrmed not only in research settings, but
also in routine diagnostic laboratories [2,14,24–26]. The
identiﬁcation of anaerobes, especially Actinomyces spp., has
been improved by the arrival of MALDI-TOF MS in clinical
laboratories [2,27–30].
Sample preparation
Most aerobic bacteria currently isolated in routine clinical
microbiology laboratories can be identiﬁed by direct transfer
from the culture medium to the target [2,25]. Some bac-
teria and most yeasts are more difﬁcult to identify with
MALDI-TOF MS, as previously described (direct transfer of
the colony onto the target). This is mostly attributable to the
quality of the spectrum obtained, but can also be linked with
the quality of the database or the limits of a technique based
mainly on ribosomal proteins (e.g. the difﬁculty in distinguish-
ing Streptococcus pneumoniae from Streptococcus mitis with
MALDI-TOF MS is congruent with 16S rDNA sequencing).
Speciﬁc protocols have been developed to improve the
quality of the spectrum. These commonly use chemical
agents to break the cell walls and expose intracellular pro-
teins. The use of these special protocols greatly improves
the ability of MALDI-TOF MS to identify yeasts [14,31].
MALDI-TOF MS on positive blood culture vials
MALDI-TOF MS has the potential to reduce the time needed
for identiﬁcation of a positive blood culture vial, especially in
the case of rapidly growing organisms, such as common
Gram-positive organisms or Enterobacteriacae. It simply
requires the immediate seeding of blood sheep agar medium,
followed by a 2–3-h incubation step, in order to obtain a
thin layer of colonies, sufﬁcient for MS. Thereafter, identiﬁca-
tion is obtained in 1 min by MALDI-TOF MS. In most cases,
the clinician will obtain the identiﬁcation of the pathogen at
least 1 day earlier.
Sometimes, however, the pathogen does not grow rapidly
enough or requires up to 48 h of anaerobic culture. In these
cases, MALDI-TOF MS performed directly on the positive
blood vial is even more outstanding in shortening the time
for identiﬁcation of a pathogen. In 2010, many studies have
been published showing good results with MALDI-TOF MS
performed directly on blood vials [3–6,32], by using more or
less simple protocols to get rid of blood, medium and human
proteins. These extraction protocols can usually be per-
formed within 1 h.
MALDI-TOF MS on clinical specimens, bypassing culture
Recent studies aimed at applying this technology directly on
urine samples, with promising results if the urine contained
more than 100 000 CFU/mL [33]. To improve the sensitivity
of MALDI-TOF MS when performed directly on clinical sam-
ples, speciﬁc protocols, based on membrane ﬁltration and
magnetic separation to collect the bacteria and obtain an
enriched solution for MS, have been employed, and have
improved the detection sensitivity of MALDI-TOF MS to
1000 CFU/mL [34].
Hardware/software/database
To our knowledge, there are two main MALDI-TOF MS
instruments presently available for routine microbiology,
commercialized by Bruker and Shimadzu. Bruker developed
its own solution, MALDI BioTyper, and Shimadzu utilizes the
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Shimadzu Launchpad software with the SARAMIS database.
These databases are large, and contain up to 2000 species
(including bacteria, yeasts and mycobacteria), with over 3000
spectra. The identiﬁcation of the microorganism relies on
the signals generated by the MALDI-TOF MS instrument, but
differs in the way in which such signals are processed, thus
explaining some differences across the various existing sys-
tems. The Bruker system concentrates on a maximum of
100 peaks, which are considered provided that they reach a
minimum signal quality; that is, they must exceed a deﬁned
signal/noise ratio. The system used by Shimadzu focuses on
peaks that are shared by a minimum number of strains from
the same species (typically 15), in order to build a reference
peak signature, called a super-spectrum.
Other systems (software/database) have been created for
routine identiﬁcation of bacteria, such as the one proposed
by Andromas, a French start-up. This system runs on both
instruments (Bruker and Shimadzu). The Andromas approach
relies on species-speciﬁc peaks that are conserved and show
a minimum relative intensity, i.e. that are higher than a
predeﬁned threshold. The data provided in this paragraph
were obtained from X. Nassif, at the start of the Andromas
FIG. 2. Technical description of matrix-assisted laser desorption ionization time-of-ﬂight mass spectrometry (MALDI-TOF MS) vs. electrospray
ionization mass spectrometry (ESI-MS). A thin layer of bacterial cells is spread across the well of a conductive metallic plate called the ‘target’.
Each specimen is then covered with a solution of acidic molecules (the ‘matrix’), which creates a mixture with the analyte molecules. The ‘target’
is then placed in the instrument, and brief laser pulses hit the mixture. The small desorbed and ionized molecules are accelerated through an
electrostatic ﬁeld and drift through a ﬁeld-free tunnel until they reach the mass spectrometer’s detector. Molecules of different masses and
charges will ‘ﬂy’ at different speeds (hence the term ‘time-of-ﬂight’). The result is a spectral signature, with spikes generally in the range of
1000–20 000 m/z (mass-to-charge ratio). This signature is then searched for in the appropriate database for the identiﬁcation of the organism to
the genus or species level, according to threshold values determined by the provider of the database. The sample (usually DNA amplicons) is
dissolved in a solvent and injected in a conductive capillary, where high voltage (V) is applied, resulting in the emission of aerosols of charged
droplets of the sample. The latter are sprayed through compartments with diminishing pressure (P), resulting in the formation of gas-phase
multiple-charged analyte ions, which then are detected by the spectrometer. ESI-MS allows high resolution, up to base composition analysis of
amplicons.
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database. The latter covers the majority of clinical pathogens
(over 500 species to date), including mycobacteria. Andro-
mas also developed a speciﬁc database for the identiﬁcation
of yeasts, Aspergillus and dermatophytes. These databases
have been used in the Necker-Enfants Malades hospital for
more than 1 year, and have provided, among 9400 identiﬁca-
tions performed routinely by over ten different technicians,
deﬁnitive identiﬁcation to the species level in 91% of cases
and to the genus level in an additional 4% (X. Nassif, unpub-
lished data). It has been developed for direct clinical use by
microbiologists, and comes with an expert system. It pro-
vides comments when the result of an identiﬁcation is not
certain to the species level, specifying whether the identiﬁca-
tion to the genus level is good enough and the reason(s) for
the incorrect identiﬁcation (e.g. related to poor spectrum
quality). The Andromas software can also be connected to a
laboratory information management system (LIMS), and has
been developed to provide alerts if the identiﬁcation is not
congruent with other results (e.g. Gram staining).
Both devices (Bruker and Shimadzu), with their respective
software and databases, have been tested in our laboratory
[25]. As conﬁrmed in other studies [2,14], the accuracy of
bacterial identiﬁcation was excellent, with high-conﬁdence
identiﬁcations for 94% (Bruker) and 88% (Shimadzu) of the
720 isolates analysed. Both instruments are easy to handle
and small enough to ﬁt in a routine laboratory, if not directly
on a simple bench. Both software applications are user-
friendly, and can easily be connected to a LIMS or to exter-
nal expert system, such as the one sold by i2A (Sirlab). The
results are returned with a scoring system, which appears to
be conservative enough to avoid false-positive identiﬁcations
with both systems. The main advantages of these systems
are speedy identiﬁcation, low running costs, low maintenance
needs and continuous improvement of the database, which is
updated on a regular basis (every 3–6 months).
Overall, the preparation of the sample and the quality of
the database seem to be determinants for the identiﬁcation
of bacteria to the species level. Therefore, the maintenance
provided by the manufacturer in terms of protocols for
preparation of the sample for speciﬁc microorganisms (e.g.
yeasts, Streptococcus viridans group and anaerobes) and
improvement of the database should heavily inﬂuence the
choice made by the clinical microbiologists. A systematic
comparison of the sensitivity and speciﬁcity of all databases
available should be performed by an independent team.
Virulence/resistance typing
More speciﬁc databases are being developed for the identiﬁ-
cation of virulence factors or speciﬁc resistances with
MALDI-TOF MS technology. Depending on the ﬂexibility of
the software, or the use of complementary software, such as
ClinProTools 2.0 (Bruker Daltonics), the MALDI-TOF MS
instrument can be used for the identiﬁcation of speciﬁc pro-
tein mass patterns, linked with the production of a virulence
factor such as Panton–Valentine leukocidin in Staphylococcus
aureus [35]. In the future, MALDI-TOF MS might allow for
the identiﬁcation of speciﬁc resistance-related proteins, such
as b-lactamases [36]. Although available software applications
provide microbiologists with possibilities to classify the
unknown bacteria into a dendrogram, MALDI-TOF MS as
used in routine microbiology (with excellent results for bac-
terial identiﬁcation) needs considerable reﬁnement for rou-
tine bacterial typing. Indeed, the variations in spectra
resulting from culture conditions, the stringent conditions
needed for optimal reproducibility and the relatively low dis-
criminative power of MALDI-TOF MS greatly limit the cur-
rent use of this tool for typing.
MALDI-RE (SEQUENOM)
There are, however, alternative technologies for typing, also
using MS methods to analyse ampliﬁcation products of PCR,
and allowing precise typing of bacteria, comparable with that
provided by multilocus sequence typing (MLST).
MALDI-RE [17] is provided by SEQUENOM (iSeq
method) [16]. To understand this approach, one should be
aware that, in contrast to the cell, the stability of DNA is
signiﬁcantly lower in the vacuum of a mass spectrometer
than that of RNA or proteins. Upon desorption, base pro-
tonation destabilizes the N-glycosidic bond, leading to base
loss and fragmentation in many positions along the DNA.
However, the 2¢-hydroxyl group of RNA enables greater sta-
bility with regard to this reaction. The iSeq method can be
described as follows (Fig. 3). Classical MLST protocols are
used with DNA samples to amplify a set of genes that
encode housekeeping proteins. Each primer is tagged with a
T7 promoter, allowing for transcription of DNA amplicons
to the more ‘stable’ RNA form. RNA strands are then
cleaved at C and U bases. The products of cleavage are anal-
ysed by MS, and their spectra are compared with the simu-
lated spectra of the reference sequences as published for
MLST. Because of the distinct mass of each nucleotide base,
the results are as good as those of conventional dideoxy
sequencing [16]. Initially, MALDI-RE was used mainly for the
detection of single-nucleotide polymorphisms, but more
recently the applications have been widely extended [37,38].
The other method available for typing is based on the use
of ESI-MS to analyse speciﬁc DNA amplicons (PCR-ESI-MS).
Ibis Biosciences has developed a tool, now commercialized
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by Abbott Molecular (PLEX-ID), that uses PCR-ESI-MS for
the identiﬁcation of most human pathogens (including
viruses), and for bacterial typing [39].
ESI-MS
Principle
Fig. 2 describes the ESI-MS process.
PCR-ESI-MS (PLEX-ID, Abbott Molecular)
As described in the introduction, clinical microbiologists are
confronted with the limitation of the time needed for culture
in their ‘need for speed’ when trying to identify the patho-
gens present in clinical samples. This need can be even more
intense when public health authorities are confronted with
potential biowarfare agents. In these situations, one requires
a tool that is able to detect human pathogens, and to per-
form bacterial typing rapidly, in order to conﬁrm the spread
of a single organism. Ibis Biosciences, now part of Abbott
Molecular, developed such a tool (Ibis T5000) on the basis
of a new technology that emerged from a programme of
research known as triangulation identiﬁcation for the genetic
evaluation of risks (TIGER) [40], mandated by biodefence
agencies in the USA.
PLEX-ID, the commercialized version of Ibis T5000, is a
nearly fully automated system that associates broad-range
PCR with ESI-MS and computerized triangulation to identify
semiquantitatively all organisms present in a sample. It allows
immediate testing of the sample, with high-throughput capa-
bilities, and provides results within 4–6 h. Owing to the rela-
tive paucity of publications on this new technology, most of
the following data on PLEX-ID are based on three papers
written by Ecker [15,41,42].
Pathogen identiﬁcation
As for any PCR-based identiﬁcation, the ﬁrst and most
limiting step of this technique is DNA extraction from clini-
Step 1: MALDI-TOF MS DATABASE IMPORT Step 2: Sample processing
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FIG. 3. Procedural steps involved in microbial typing by matrix-assisted laser desorption ionization time-of-ﬂight mass spectrometry (MALDI-
TOF MS). Step 1: import of reference sequences into the system database. Step 2: PCR and post-PCR biochemistry. Step 3: MALDI-TOF MS
spectrum and peak pattern comparison. Step 4: tabulated typing results. Figure and legend reproduced with permission from ‘Proceedings of the
National Academy of Sciences of the United States of America’ (PNAS), article by Honisch C, Chen Y, Mortimer C, Arnold C, Schmidt O, van
den BD et al. Automated comparative sequence analysis by base-speciﬁc cleavage and mass spectrometry for nucleic acid-based microbial typing.
Proc Natl Acad Sci USA 2007; 104(25):10649–10654. Copyright 2007 National Academy of Sciences, USA.
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cal samples. In order to improve detection sensitivity, the
instrument uses permissive PCR conditions during the ﬁrst
cycles (to improve hybridization) and multiple primers.
Broad-spectrum ampliﬁcation by PCR (targeting ribosomal
genes and housekeeping protein genes) is coupled with ESI-
MS, as shown in Fig. 4. The latter allows the determination
of the base composition of each amplicon with high accuracy,
but not with the linking order. Computerized triangulation is
used for the identiﬁcation of organisms to the species level
[41,42].
Quantiﬁcation
With clinical specimens such as sputum, the use of PLEX-ID
may provide more than one bacterium. Therefore, there is a
need for quantiﬁcation. This is achieved by adding to each
PCR reaction a nucleic acid with known concentration, with
a sequence similar to that of the target, but that can be
unambiguously distinguished. It also serves as an internal
positive control. Comparison of peak heights across the ana-
lyte and the control can then provide semiquantiﬁcation
[15].
Typing, virulence and resistance
Regions of high variability are routinely ampliﬁed with the
use of the 16 primers, and intraspecies variability appears.
This provides distinguishing ﬁngerprints, and it is proposed
that this may permit the tracking of a pathogen causing an
epidemic. For the detection of virulence or resistance, spe-
ciﬁc primers may be added to the assay [41]. Examples
include the mecA gene for methicillin resistance, the vanA
and vanB genes for vancomycin resistance in enterococci,
and the blaKPC gene for resistance to carbapenems. In princi-
ple, and because of the relatively high multiplexing potential
of the method, this could be extended to other known resis-
tance or virulence genes. It has even been proposed that
PLEX-ID may allow precise genotyping with the same prim-
ers as used for MLST [15]. However, to our knowledge, in
contrast to the situation with MALDI-RE, this has not yet
been demonstrated formally.
Conclusions regarding PLEX-ID
The identiﬁcation mode of the PCR-ESI-MS tool suits the
need for rapid identiﬁcation directly from a specimen, with a
result being provided within 4–6 h. It may also provide sup-
port for infection control specialists (e.g. partial typing, for
characterization of pathogens). Because of its use of broad-
range primers, it can be used as a tool for analysis for syn-
dromic panels of infection, such as respiratory viruses. A
good example of this is the use of PLEX-ID for the pandemic
H1N1 virus in 2009 (S. Penugonda, Poster PIV2, 12th ESCV,
FIG. 4. The PLEX-ID technology. Step 1: extraction of microbial DNA from the clinical sample. All of the following steps take place in the
PLEX-ID instrument and are fully automated. Step 2: PCR ampliﬁcation with primers targeting ribosomal and housekeeping protein genes. Step 3:
determination of the base composition of the amplicons (no linking order) by electrospray ionization mass spectrometry (ESI-MS). Step 4: com-
puterized triangulation of the base composition of several genomic regions is used to identify the microorganism.
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2009). Clinical researchers may ﬁnd wider applications for
this technology, similar to microarrays but faster.
Capillary and Next-generation Sequencing
These sequencing methods are clearly out of the scope of
this review, but are mentioned here, as well as in Table 1, in
order to facilitate comparison of the use of the various MS
techniques in the ﬁeld of clinical microbiology. The inter-
ested reader is invited to refer to Metzker’s article [43] for
an updated review on next-generation sequencing, to Mai-
den’s [44] for the description of MLST, and to Palacios’s [45]
for the use of high-throughput sequencing for identiﬁcation
of microbial sequences not found by any other method
available.
Conclusions
MS has taken many years to enter the ﬁeld of routine micro-
biology. However, MALDI-TOF MS is about to become the
standard of identiﬁcation for positive cultures in most labora-
tories. Future applications of MALDI-TOF MS will certainly
be developed, with various enrichment procedures, in order
to provide more direct identiﬁcation on clinical specimens,
and for the detection of speciﬁc virulence or resistance pro-
tein markers.
New technologies, such as MALDI-RE, have shown excel-
lent results for bacterial genotyping, and are much faster
than conventional MLST.
PCR-ESI-MS is currently a potential application of MS for
direct microbial identiﬁcation. It is providing results similar
to those from microarrays but faster. Clinical studies to eval-
uate the sensitivity and speciﬁcity of PCR-ESI-MS as com-
pared with blood cultures and established direct nucleic acid
detection technologies should be undertaken to assess its
potential in diagnostics. With the rapid development of
molecular identiﬁcation tools, one still needs to remember
that traditional cultures remain essential, at least until valid
and affordable alternatives to phenotypic antibiotic suscepti-
bility testing emerge.
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